LAUSANNE, SWITZERLAND / ACCESSWIRE / June 30, 2023 / Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas…
Link to original post
![Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas](https://bearingbuzz.com/wp-content/uploads/2023/06/9373-novigenix-reports-interim-european-validation-data-on-its-new-ngs-based-whole-blood-rna-signature-for-detection-of-advanced-colorectal-adenomas.jpg)
![Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas](https://bearingbuzz.com/wp-content/uploads/2023/06/9373-novigenix-reports-interim-european-validation-data-on-its-new-ngs-based-whole-blood-rna-signature-for-detection-of-advanced-colorectal-adenomas.jpg)